Drugs / emtricitabine with tenofovir alafenamide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02121795 | May 2014 → Aug 2015 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | emtricitabine with tenofovir alafenamide | “We aimed to further assess safety and efficacy of fixed-dose combination emtricitabine with tenofovir alafenamide in patients switched from emtricitabine with tenofovir...” PMID 27036991 ↗ Mar 2016 |
| Known as | F/TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02121795 ↗ |
| Modality | Small molecule | “With its safety advantages, fixed-dose emtricitabine with tenofovir alafenamide has the potential to become an important NRTI backbone.” PMID 27036991 ↗ Mar 2016 |
| Route | Oral | “Tablets administered orally once daily” NCT02121795 ↗ |